A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens
Abstract Previously, cytotoxic drugs were the only option for patients with non‐small cell lung cancer (NSCLC) and the prognosis was poor. However, molecularly targeted therapies and immune checkpoint inhibitors represent a breakthrough in the treatment of advanced NSCLC and have improved survival r...
Main Authors: | Satoshi Tanaka, Nobuaki Yoshimura, Ryo Asakawa, Satoshi Tobita, Moto Yaga, Kiyonobu Ueno |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-09-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.15041 |
Similar Items
-
Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report
by: Liang Dong, et al.
Published: (2018-01-01) -
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
by: Long-Hua Guo, et al.
Published: (2020-09-01) -
Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
by: Lin Z, et al.
Published: (2017-11-01) -
Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
by: Bo Jia, et al.
Published: (2020-12-01) -
Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
by: Yan Wang, et al.
Published: (2018-03-01)